The Short Version
Compounded tirzepatide (the active ingredient in Mounjaro and Zepbound) is no longer legally available from compounding pharmacies as of March 2025. The FDA declared the tirzepatide shortage resolved in October 2024, enforcement discretion ended in March 2025, and a federal court upheld the decision in May 2025. This guide explains the full timeline and what options remain.
Timeline of Events
| Date | Event |
|---|---|
| 2022 | Mounjaro (tirzepatide) approved for T2D; demand surges |
| 2023 | Zepbound approved for weight management; chronic shortages begin |
| 2023-2024 | FDA shortage designation allows compounding pharmacies to produce tirzepatide legally |
| October 2, 2024 | FDA initially declares the tirzepatide shortage resolved |
| October 22, 2024 | Court remands the decision back to FDA for reevaluation (OFA lawsuit) |
| December 19, 2024 | FDA re-confirms the shortage is resolved after review |
| February 18, 2025 | Enforcement discretion ends for 503A pharmacies |
| March 19, 2025 | Enforcement discretion ends for 503B outsourcing facilities |
| May 7, 2025 | Federal district court upholds the FDA's shortage resolution |
| 2025-2026 | OFA appeals to Fifth Circuit (pending); Eli Lilly files lawsuits against compounders and telehealth platforms (mixed results) |
Why Compounding Was Legal (Temporarily)
Under federal law, compounding pharmacies can produce copies of FDA-approved drugs only when those drugs are on the FDA's official shortage list. When tirzepatide was in shortage (2023-2024), compounders could legally produce it to fill the gap.
Once Eli Lilly ramped up manufacturing and the FDA declared the shortage resolved, the legal basis for broad compounding evaporated. The Outsourcing Facilities Association (OFA) challenged the decision in court, leading the FDA to remand and then re-confirm the resolution in December 2024. This isn't unique to tirzepatide — it's how the framework works for all drugs, and the same process has now played out with semaglutide (shortage removed February 2025).
What About "Modified" Tirzepatide?
Some compounding pharmacies continue to offer products they describe as tirzepatide with modifications:
- Added ingredients — B12, L-carnitine, or other compounds added to the formulation
- Different salt forms — tirzepatide sodium vs. the original acetate form
- Altered delivery — sublingual drops or alternative concentrations
Is This Legal?
This is a gray area under active regulatory pressure. The argument is that a meaningfully different formulation isn't a "copy" of the approved drug. The FDA has not explicitly endorsed this interpretation, and enforcement actions could come at any time.
Safety Concern: Tirzepatide + B12 Impurity
A 2026 medRxiv preprint identified a previously unknown chemical impurity that forms when tirzepatide is combined with B12 analogs (cyanocobalamin). The reaction produces an uncharacterized compound with unknown safety implications. Eli Lilly issued an open letter warning about this risk. If you are using a compounded tirzepatide/B12 combination product, discuss this finding with your prescriber.
If you're considering a "modified tirzepatide" product, understand that you are accepting both regulatory and safety risk. The FDA could move to shut down these products, and the legal protection is uncertain at best.
What Are the Alternatives?
Legal Options
| Option | Details | Cost | Notes |
|---|---|---|---|
| Brand Mounjaro/Zepbound | FDA-approved, from Eli Lilly | $800-1,200/month | Insurance may cover for T2D; weight management coverage varies |
| Compounded semaglutide | Restricted — shortage ended Feb 2025; 503A patient-specific compounding continues under legal challenge | $129-299/month | Different mechanism (GLP-1 only vs. dual agonist); availability varies |
| Brand Ozempic/Wegovy | FDA-approved semaglutide | $800-1,600/month | Insurance coverage varies |
| Manufacturer savings programs | Eli Lilly and Novo Nordisk offer copay cards | Varies | Check manufacturer websites for eligibility |
Research Vendor Option
Some research vendors continue to sell tirzepatide as a research chemical. This carries the same risks as any gray market peptide — no sterility guarantees, no physician oversight, no legal protection, and no quality assurance beyond the vendor's own COA.
Impact on Compounding Pharmacies
The tirzepatide shutdown significantly affected the compounding industry:
- Revenue loss — tirzepatide was the highest-revenue compounded product for many pharmacies
- Litigation — Eli Lilly actively pursued legal action against compounders
- Patient disruption — hundreds of thousands of patients lost access to affordable tirzepatide
- Industry uncertainty — raised questions about how long semaglutide compounding will remain legal
Could It Come Back?
For compounding to resume legally, one of the following would need to happen:
- New shortage declaration — if Eli Lilly's supply falters again and the FDA redeclares a shortage
- Legislative change — Congress could modify the compounding framework, though this is unlikely in the near term
- Successful legal challenge — the Outsourcing Facilities Association's appeal to the Fifth Circuit is still pending as of April 2026. A favorable ruling could reopen compounding access.
Note: Eli Lilly has filed its own lawsuits against compounders (Strive, Empower) and telehealth platforms (Mochi Health, Willow Health, and others), but these have had mixed results — courts have dismissed several of these cases. The legal landscape remains unsettled.
The Semaglutide Question
The same framework that ended tirzepatide compounding has now affected semaglutide. The FDA removed semaglutide from the shortage list on February 21, 2025. While 503A pharmacies continue patient-specific compounding under a narrower legal framework, broad shortage-based compounding has ended — mirroring the tirzepatide timeline.
If you're currently using compounded semaglutide, confirm availability directly with your pharmacy. The legal landscape for semaglutide compounding is actively being litigated and could change further.
Key Takeaways
- Compounded tirzepatide is not currently legal under the shortage framework — standard or otherwise
- "Modified" versions exist in a regulatory gray area with uncertain enforcement and emerging safety concerns (B12 impurity)
- Compounded semaglutide is in a similar position — the FDA removed it from the shortage list in February 2025, though 503A patient-specific compounding continues under legal challenge
- Brand Mounjaro/Zepbound is the only fully legal tirzepatide option
- The compounding framework is drug-shortage-dependent — when the shortage ends, broad compounding ends
- The Fifth Circuit appeal on the tirzepatide shortage resolution is still pending and could affect the legal landscape